CC
VRTX icon

ClearArc Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

ClearArc Capital’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$601K Sell
2,744
-1,126
-29% -$228K 0.23% 105
2019
Q3 		$656K Buy
3,870
+64
+2% +$11.3K 0.19% 134
2019
Q2 		$698K Sell
3,806
-472
-11% -$82.5K 0.21% 117
2019
Q1 		$787K Sell
4,278
-108
-2% -$19.9K 0.21% 113
2018
Q4 		$727K Sell
4,386
-2,204
-33% -$382K 0.22% 112
2018
Q3 		$1.27M Buy
6,590
+72
+1% +$12.8K 0.17% 132
2018
Q2 		$1.11M Buy
6,518
+56
+0.9% +$8.68K 0.16% 147
2018
Q1 		$1.05M Buy
6,462
+10
+0.2% +$1.63K 0.16% 147
2017
Q4 		$967K Sell
6,452
-30
-0.5% -$4.44K 0.13% 159
2017
Q3 		$986K Buy
6,482
+349
+6% +$52.5K 0.15% 148
2017
Q2 		$790K Buy
6,133
+37
+0.6% +$4.45K 0.13% 180
2017
Q1 		$667K Buy
6,096
+86
+1% +$7.57K 0.11% 194
2016
Q4 		$443K Sell
6,010
-81
-1% -$6.59K 0.08% 259
2016
Q3 		$531K Buy
6,091
+98
+2% +$9.26K 0.1% 226
2016
Q2 		$516K Sell
5,993
-35
-0.6% -$3.02K 0.1% 223
2016
Q1 		$479K Buy
6,028
+33
+0.6% +$2.98K 0.1% 231
2015
Q4 		$754K Buy
5,995
+35
+0.6% +$4.22K 0.16% 158
2015
Q3 		$621K Sell
5,960
-76
-1% -$9.76K 0.13% 206
2015
Q2 		$745K Buy
6,036
+784
+15% +$98.8K 0.14% 192
2015
Q1 		$620K Buy
5,252
+113
+2% +$13.5K 0.13% 201
2014
Q4 		$611K Buy
5,139
+229
+5% +$25.8K 0.12% 196
2014
Q3 		$551K Buy
4,910
+151
+3% +$14.4K 0.12% 199
2014
Q2 		$451K Buy
4,759
+95
+2% +$6.66K 0.1% 226
2014
Q1 		$330K Buy
4,664
+302
+7% +$23.9K 0.08% 279
2013
Q4 		$324K Sell
4,362
-251
-5% -$17.5K 0.08% 259
2013
Q3 		$350K Buy
+4,613
New +$367K 0.1% 233

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ClearArc Capital's VRTX Position: Q4 2019 in Review

ClearArc Capital reduced its Vertex Pharmaceuticals (VRTX) stake by 29% in Q4 2019, selling an estimated $228K and leaving 2,744 shares worth $601K. The position accounts for 0.23% of the portfolio, ranked #105.

ClearArc Capital first reported a position in VRTX in Q3 2013 and has held it in 26 quarters since. The position peaked at $1.27M in Q3 2018. 814 funds tracked by Wall St. Rank hold VRTX as of Q4 2019.

  • ClearArc Capital held 2,744 shares of Vertex Pharmaceuticals worth $601K as of Q4 2019.
  • ClearArc Capital sold 1,126 Vertex Pharmaceuticals shares in Q4 2019, an estimated $228K.
  • Vertex Pharmaceuticals made up 0.23% of ClearArc Capital's portfolio in Q4 2019, its #105 holding.
  • ClearArc Capital first reported a position in Vertex Pharmaceuticals in Q3 2013 and has held it in 26 quarters since.
  • ClearArc Capital's Vertex Pharmaceuticals position peaked at $1.27M in Q3 2018.
  • 814 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2019.

Based on ClearArc Capital's 13F filing for Q4 2019, filed 14 Feb 2020.